A 12-week, Phase 2, Randomized, Double-blind, Placebo-controlled, Parallel Group Study To Evaluate The Efficacy And Safety Of Once Daily Pf-06291874 Administration In Adults With Type 2 Diabetes Mellitus Inadequately Controlled On Metformin
Latest Information Update: 16 Jan 2020
At a glance
- Drugs PF 6291874 (Primary)
 - Indications Type 2 diabetes mellitus
 - Focus Therapeutic Use
 - Sponsors Pfizer
 
Most Recent Events
- 13 Jun 2017 Results (n=174) presented at the 77th Annual Scientific Sessions of the American Diabetes Association
 - 15 Sep 2016 Status changed from active, no longer recruiting to completed.
 - 16 Aug 2016 Status changed from recruiting to active, no longer recruiting.